MedTrace Logo

Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients

NCT03850626 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 168

Last updated 2021-03-26

No results posted yet for this study

Summary

The CSMS was defined by the European Academy of Allergy and Immunology Taskforce as a standardised tool to assess clinical effects of allergen-specific immunotherapy (AIT). The aim of this study is to validate the CSMS as a tool to assess the clinical effects of Depigoid AIT, so that the CSMS can be used in future studies as a primary endpoint as well as a comparative parameter.

Conditions

  • Allergic Rhinoconjunctivitis
  • Allergic Asthma

Interventions

BIOLOGICAL

Immunotherapy

subcutaneous injection

Sponsors & Collaborators

  • Leti Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Angelika Sager, Dr.med. · Medical Department

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-09
Primary Completion
2020-09-03
Completion
2020-09-03

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03850626 on ClinicalTrials.gov